Please use this identifier to cite or link to this item:
https://elib.bsu.by/handle/123456789/289894| Title: | Dft calculations and in silico study of chlorogenic, ellagic and quisqualic acids as potential inhibitors of sars-cov-2 main protease mpro |
| Authors: | Shahab, Siyamak Kaviani, Sadegh Sheikhi, Masoome Almodarresiyeh, Hora Alhosseini Saud, Sultan Al |
| Keywords: | ЭБ БГУ::ЕСТЕСТВЕННЫЕ И ТОЧНЫЕ НАУКИ::Химия |
| Issue Date: | 2022 |
| Publisher: | AMG Transcend Association |
| Citation: | Biointerface Res Appl Chem 2022;12(1):61-73. |
| Abstract: | In the present work, at first, density functional theory calculations were performed to investigate the molecular structure of the Chlorogenic, Ellagic, and Quisqualic acids by CAMB3LYP/MidiX level of theory. A detail of quantum molecular descriptors of the title compounds such as ionization potential (IP) and Electron Affinities (EA), Hardness (η), Softness (S), Electronegativity (), Electrophilic Index (), Electron Donating Power (-), Electron Accepting Power (+) and Energy Gap (Eg) have been calculated. Pharmacokinetic properties of the title compounds and their bioactivity were investigated. In the following, a molecular docking study was carried out to screen for an effective available compound that may work as a strong inhibitor for the SARS-CoV-2 main protease Mpro. The binding energy between SARS-CoV-2 main protease Mpro and title organic acids showed a good binding affinity. Therefore, the Chlorogenic, Ellagic, and Quisqualic acids can be used for potential application against the SARS-CoV-2 main protease Mpro. |
| URI: | https://elib.bsu.by/handle/123456789/289894 |
| DOI: | 10.1016/j.matchemphys.2022.125703 |
| Scopus: | 85113276723 |
| Licence: | info:eu-repo/semantics/openAccess |
| Appears in Collections: | Научные публикации, проиндексированные в SCOPUS и WoS |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 20695837121.061073.pdf | 710,13 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

